Ascentage Pharma (AAPG) said Monday that two of its drug candidates, lisaftoclax and olverembatinib, were included in the 2025 Chinese Society of Clinical Oncology Guidelines.
The company said lisaftoclax is first recommended in the CSCO guidelines as a potential treatment for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
The investigational drug is currently under priority review in China following a November 2024 new drug application, Ascentage said.
Olverembatinib received an upgraded recommendation for use in children with leukemia and retained several existing recommendations for adult leukemia treatment, according to the company.
Ascentage said the drug remains part of China's national reimbursement drug list and is co-marketed in the country with Innovent Biologics.
The investigational drugs have not been approved in the US, Ascentage added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.